Success of a steroid-minimization immunosuppression protocol for renal transplantation in the presence of donor-specific antibodies

Pediatric Transplantation

Volumn 13, Issue 5, 2009, Pages 624-627

  Butani, Lavjay ^a   Perez, Richard V ^a   Gallay, Brian J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Corticosteroids; Donor specific antibody; Kidney; Minimization; Pediatric; Positive cross match; Transplantation

Indexed keywords

AMLODIPINE; CARVEDILOL; CREATININE; DOMOR SPECIFIC ANTIBODY; ENALAPRIL; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE GRAFT REJECTION; ANTIBODY TITER; ARTICLE; BACTEREMIA; CASE REPORT; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; DEATH; FLOW CYTOMETRY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; NEPHRECTOMY; PERITONEAL DIALYSIS; PLASMAPHERESIS; REPEATED DRUG DOSE; RESPIRATORY DISTRESS; SINGLE DRUG DOSE; STEROID THERAPY; TREATMENT OUTCOME;

ANTIBODIES; FATAL OUTCOME; FLOW CYTOMETRY; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; STEROIDS; TIME FACTORS;

EID: 67651180885     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.01025.x     Document Type: Article

References (8)

1. Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O Jr. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003 : 76 : 1331 1339.
2. Lau KK, Haddad MN, Berg GM, Perez RV, Butani L. Rapid steroid discontinuation for pediatric renal transplantation: A single center experience. Pediatr Transplant 2007 : 11 : 504 510.
3. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004 : 4 : 1033 1041.
4. Colombo MB, Haworth SE, Poli F, et al. Luminex technology for anti-HLA antibody screening: Evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom 2007 : 72 : 465 471.
5. Kerman R, Stepkowski S, Knight R, et al. Clinical relevance of crossmatch results, HLA and non-HLA antibodies for renal allograft recipients. In : World Transplant Congress Abstract Booklet. 2006 : pp. 782.
6. Akalin E, Bromberg JS. Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 2005 : 66 : 359 363. (Pubitemid 40615790)
7. Seemayer CA, Gaspert A, Nickeleit V, Mihatsch MJ. C4d staining of renal allograft biopsies: A comparative analysis of different staining techniques. Nephrol Dial Transplant 2007 : 22 : 568 576.
8. Khwaja K, Asolati M, Harmon J, et al. Outcome at 3 years with a prednisone-free maintenance regimen: A single-center experience with 349 kidney transplant recipients. Am J Transplant 2004 : 4 : 980 987.